PRESS-RELEASE filed Aug 10, 2026 at 16:05 ET
Sana Biotechnology reported Q2 2026 GAAP net loss of $63.6M ($0.22/share), slightly narrower than the year-ago $93.8M loss ($0.39/share), driven by the absence of a $44.6M impairment and lower R&D spend. Non-GAAP net loss per share was $0.13, comparing favorably to $0.16 a year ago. The company ended Q2 with $160.5M cash, projecting runway into mid-2027 after raising $93.3M from ATM sales and Mayo Clinic equity investment. Key pipeline catalysts remain on track: SC451 IND/Phase 1/2 start for type 1 diabetes as early as this year, and first-in-human data for SG293 in non-Hodgkin lymphoma also expected this year.